184 related articles for article (PubMed ID: 35530288)
21. Enhancement of cisplatin-induced apoptosis by β-elemene in resistant human ovarian cancer cells.
Li QQ; Lee RX; Liang H; Zhong Y; Reed E
Med Oncol; 2013 Mar; 30(1):424. PubMed ID: 23277286
[TBL] [Abstract][Full Text] [Related]
22. β-Elemene promotes cisplatin-induced cell death in human bladder cancer and other carcinomas.
Li QQ; Wang G; Liang H; Li JM; Huang F; Agarwal PK; Zhong Y; Reed E
Anticancer Res; 2013 Apr; 33(4):1421-8. PubMed ID: 23564782
[TBL] [Abstract][Full Text] [Related]
23. Beta-elemene: A phytochemical with promise as a drug candidate for tumor therapy and adjuvant tumor therapy.
Feng Y; An Q; Zhao Z; Wu M; Yang C; Liang W; Xu X; Jiang T; Zhang G
Biomed Pharmacother; 2024 Mar; 172():116266. PubMed ID: 38350368
[TBL] [Abstract][Full Text] [Related]
24. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
[TBL] [Abstract][Full Text] [Related]
25. Synergistic Cytotoxicity of β-Elemene and Cisplatin in Gingival Squamous Cell Carcinoma by Inhibition of STAT3 Signaling Pathway.
Huang C; Yu Y
Med Sci Monit; 2017 Mar; 23():1507-1513. PubMed ID: 28355175
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA‑22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Xue HQ; Sun L; Sun C; Feng W; Guo SB
Oncol Rep; 2020 Apr; 43(4):1169-1186. PubMed ID: 32323781
[TBL] [Abstract][Full Text] [Related]
27. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
28. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
29. β-Elemene inhibits the metastasis of multidrug-resistant gastric cancer cells through miR-1323/Cbl-b/EGFR pathway.
Deng M; Liu B; Song H; Yu R; Zou D; Chen Y; Ma Y; Lv F; Xu L; Zhang Z; Lv Q; Yang X; Che X; Qu X; Liu Y; Zhang Y; Hu X
Phytomedicine; 2020 Apr; 69():153184. PubMed ID: 32199253
[TBL] [Abstract][Full Text] [Related]
30. Anticancer effects of β-elemene with hyperthermia in lung cancer cells.
Wu Z; Wang T; Zhang Y; Zheng Z; Yu S; Jing S; Chen S; Jiang H; Ma S
Exp Ther Med; 2017 Jun; 13(6):3153-3157. PubMed ID: 28588670
[TBL] [Abstract][Full Text] [Related]
31. Synergistic antitumor effect of dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with cisplatin on drug-resistant non-small cell lung cancer cell.
Zhu H; Shi Y; Jiao X; Yang G; Wang R; Yuan Y
Oncol Lett; 2020 Dec; 20(6):326. PubMed ID: 33123242
[TBL] [Abstract][Full Text] [Related]
32. Cbl-regulated Akt and ERK signals are involved in β-elemene-induced cell apoptosis in lung cancer cells.
Li L; Xu L; Qu X; Zhao M; Yu P; Kang J; Liu Y; Hu X
Mol Med Rep; 2011; 4(6):1243-6. PubMed ID: 21837364
[TBL] [Abstract][Full Text] [Related]
33. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
[TBL] [Abstract][Full Text] [Related]
34. An ATF
Zhai B; Chen P; Wang W; Liu S; Feng J; Duan T; Xiang Y; Zhang R; Zhang M; Han X; Chen X; Li Q; Li G; Liu Y; Huang X; Zhang W; Pan T; Yan L; Jin T; Xie T; Sui X
Cancer Biol Med; 2020 Aug; 17(3):676-692. PubMed ID: 32944399
[No Abstract] [Full Text] [Related]
35. β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK.
Li QQ; Lee RX; Liang H; Wang G; Li JM; Zhong Y; Reed E
Int J Oncol; 2013 Sep; 43(3):721-8. PubMed ID: 23817665
[TBL] [Abstract][Full Text] [Related]
36. Discovery of novel antitumor nitric oxide-donating β-elemene hybrids through inhibiting the PI3K/Akt pathway.
Chen J; Wang T; Xu S; Zhang P; Lin A; Wu L; Yao H; Xie W; Zhu Z; Xu J
Eur J Med Chem; 2017 Jul; 135():414-423. PubMed ID: 28463784
[TBL] [Abstract][Full Text] [Related]
37. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
[TBL] [Abstract][Full Text] [Related]
38. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
39. Reversion of malignant phenotypes of human glioblastoma cells by β-elemene through β-catenin-mediated regulation of stemness-, differentiation- and epithelial-to-mesenchymal transition-related molecules.
Zhu T; Li X; Luo L; Wang X; Li Z; Xie P; Gao X; Song Z; Su J; Liang G
J Transl Med; 2015 Nov; 13():356. PubMed ID: 26563263
[TBL] [Abstract][Full Text] [Related]
40. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells.
Li H; Hu J; Wu S; Wang L; Cao X; Zhang X; Dai B; Cao M; Shao R; Zhang R; Majidi M; Ji L; Heymach JV; Wang M; Pan S; Minna J; Mehran RJ; Swisher SG; Roth JA; Fang B
Oncotarget; 2016 Jan; 7(3):3548-58. PubMed ID: 26657290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
